In the latest Global AI Competitiveness Index focused on life sciences, China secured third place behind the United States and United Kingdom, marking significant progress in AI-driven biotechnology, healthcare, and longevity sectors.
- China ranks third globally in AI for biotech and healthcare
- Government aims for AI-assisted diagnosis nationwide by 2030
- Hong Kong emerges as a leading city hub in biomedical AI innovation
What happened
China was named third in the latest Global AI Competitiveness Index released by the Deep Knowledge Group, a consortium that researches and invests in deep technology. The ranking evaluates countries on their AI capabilities specifically in life sciences domains including biotechnology, healthcare, and longevity. China’s score of 85.3 places it behind only the US and UK, highlighting its strong presence in AI development, research talent, and biotech scale.
The report also ranked Hong Kong third among city-level AI innovation hubs, following Boston and San Francisco. Hong Kong’s strengths include access to capital markets, institutional credibility, and close ties to the Greater Bay Area, boosting its role as a biomedical AI center.
Why it matters
China’s rise in AI competitiveness reflects a strategic shift from broad general AI applications towards specialized, heavily regulated fields like drug discovery and clinical diagnostics. Success in these areas demands robust infrastructure for data governance, regulatory alignment, and the clinical validation of AI models, beyond just research volume or raw technology power.
The national plan launched by China’s health authorities aims to make AI-assisted diagnostic and treatment tools widely available in primary care institutions by 2030, signaling a commitment to transform healthcare delivery through AI. This approach can potentially improve medical outcomes across its vast population and position China as a leader in the AI-driven life sciences economy.
What to watch next
Future developments will include monitoring how China implements its nationwide AI healthcare deployment, especially the integration of AI in hospitals and clinics at local levels. Progress will also depend on creating the regulatory frameworks and data infrastructure necessary for safe, effective AI use in medical applications.
Additionally, Hong Kong’s growing role as a biomedical AI hub within the Greater Bay Area will be important to watch. The city’s efforts focus on generating real-world clinical data, supporting AI-enabled workflows, and bridging technology with regulatory and commercial pathways. Success here could strengthen the region’s competitive advantage in medical AI innovation.